18 completed, 4 recruiting, 3 withdrawn, 2 terminated. 14 Phase 2, 6 Phase 1, 6 Phase 3, 5 Not applicable, 5 Phase 4.
Follow Visudyne: new trials by email Literature Review of Visudyne trials Research Report on Visudyne
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SCARFREE-001: Verteporfin for Scar Prevention Verteporfin Injection, Saline injection - Surgical Scar | Phase 2 | Recruiting | Odense University Hospital | 12 | 2026-10-01 | 2026-10-27 |
| Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System Photodynamic Therapy (PDT), Verteporfin Injection - Prostate Cancer | Phase 1 / Phase 2 | Recruiting | SpectraCure AB | 43 | 2025-01-06 | 2026-05-01 |
| Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 24 | 2024-12-06 | 2026-06-18 |
| Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction Biospecimen Collection, Computed Tomography, Endobronchial Ultrasound Bronchoscopy - Malignant Solid Neoplasm | Phase 1 / Phase 2 | Recruiting | Roswell Park Cancer Institute | 42 | 2024-10-01 | 2026-04-06 |
| Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide - Exudative Age Related Macular Degeneration | Phase 4 | Withdrawn | Wake Forest University Health Sciences | 2023-03-30 | 2024-03-22 | |
| Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment Aflibercept + reduced fluence photodynamic therapy (RF-PDT), Aflibercept + sham reduced fluence photodynamic therapy (RF-PDT) - Polypoidal Choroidal Vasculopathy | Not applicable | Completed | Singapore National Eye Centre | 60 | 2021-02-01 | 2025-11-18 |
| Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma Verteporfin - Glioblastoma, Recurrent Glioblastoma | Phase 1 / Phase 2 | Terminated | Emory University | 9 | 2021-01-15 | 2026-10-28 |
| Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study Endoscopic Ultrasound, Fluorescence Imaging, Photodynamic Therapy - Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Carcinoma | Phase 2 | Completed | Mayo Clinic | 13 | 2017-05-31 | 2025-07-30 |
| Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System Verteporfin, SpectraCure P18 System - Recurrent Prostate Cancer | Phase 1 / Phase 2 | Recruiting | SpectraCure AB | 66 | 2017-03-21 | 2026-05-01 |
| Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD Aflibercept, Triamcinolone Acetonide, Verteporfin - Neovascular Age-related Macular Degeneration | Not applicable | Withdrawn | Duke University | 2016-01-01 | 2017-07-26 | |
| Aflibercept in Polypoidal Choroidal Vasculopathy Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321), Visudyne - Neovascular Macular Degeneration | Phase 4 | Completed | Bayer | 333 | 2014-05-29 | 2020-12-02 |
| Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Ranibizumab 0.5mg, Ranibizumab 0.5 mg, Verteporfin PDT - Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM) | Phase 3 | Completed | Novartis Pharmaceuticals | 457 | 2013-09-11 | 2019-06-24 |
| ICG-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities: A Pilot Study Visudyne - Retinal Vascular Disorders | Not applicable | Unknown | Manhattan Eye, Ear & Throat Hospital | 30 | 2013-04-01 | 2013-11-01 |
| Treatment of Primary Breast Cancer Using PDT Verteporfin - Breast Neoplasms | Not applicable | Completed | University College, London | 12 | 2013-01-01 | 2018-04-06 |
| VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration) Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321), Visudyne - Macular Degeneration | Phase 3 | Completed | Bayer | 304 | 2011-12-01 | 2016-11-04 |
| Photodynamic Therapy for the Treatment of Vertebral Metastases Visudyne - Vertebral Metastases | Phase 1 | Completed | Sunnybrook Health Sciences Centre | 30 | 2011-06-01 | 2018-02-15 |
| Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Verteporfin, ranibizumab - Chronic Central Serous Chorioretinopathy | Phase 1 / Phase 2 | Completed | Jang Won Heo | 34 | 2009-07-01 | 2013-05-27 |
| Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy Verteporfin PDT, half-dose, verteporfin PDT, half-fluence - Central Serous Chorioretinopathy | Not applicable | Completed | Shin Kong Wu Ho-Su Memorial Hospital | 24 | 2008-11-01 | 2011-07-25 |
| Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy Verteporfin Photodynamic Therapy, Ranibizumab - Polypoidal Choroidal Vasculopathy | Phase 4 | Completed | Novartis | 61 | 2008-04-01 | 2011-04-19 |
| Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis ranibizumab, verteporfin - Presumed Ocular Histoplasmosis (POHS) | Phase 2 | Unknown | Barnes Retina Institute | 30 | 2007-10-01 | 2009-04-16 |
Showing 20 of 30. Sign in to see all of them.
Macular Degeneration (14) · Choroidal Neovascularization (7) · Pancreatic Neoplasms (2) · Polypoidal Choroidal Vasculopathy (2) · Prostatic Neoplasms (2) · Breast Neoplasms (1) · Central Serous Chorioretinopathy (1) · Cicatrix (1) · Glioblastoma (1) · Histoplasmosis (1) · Neovascularization, Pathologic (1) · Polyps (1) · Vision Disorders (1)
Novartis (3) · Bayer (2) · Manhattan Eye, Ear & Throat Hospital (2) · Mayo Clinic (2) · Novartis Pharmaceuticals (2) · SpectraCure AB (2) · Barnes Retina Institute (1) · Duke University (1) · Emory University (1) · Illinois Retina Associates (1) · Jang Won Heo (1) · Odense University Hospital (1) · Oklahoma State University Center for Health Sciences (1) · QLT Inc. (1) · Roswell Park Cancer Institute (1)
United States (17) · Canada (5) · South Korea (4) · Germany (3) · Hong Kong (3) · Singapore (3) · Taiwan (3) · United Kingdom (3) · China (2) · Denmark (2) · Hungary (2) · Switzerland (2) · Thailand (2) · Australia (1) · Austria (1)
Allen Ho, MD (1) · Andrew Strong, Ph.D (1) · Cheng-Kuo Cheng, MD (1) · David Callanan, MD (1) · David Hebbelstrup Jensen, MD, Ph.d. (1) · Gemmy Cheung Chui Ming (1) · Henry Hudson, MD (1) · Jang Won Heo, Professor (1) · John Saurino, DO (1) · Jonathan Fainberg, MD, MPH (1) · Kevin J. Blinder, MD (1) · Lawrence A. Yannuzzi, M.D. (1)
PMID 40522203, PMID 21742303, PMID 22424834, PMID 22426346, PMID 22444829, PMID 23410808, PMID 25079064, PMID 25758601, PMID 29801063, PMID 33647286, PMID 34261044, PMID 34266844, PMID 40146166, PMID 41903075
P01CA084203 (2), 2025 (1), P30CA138292 (1), R01CA283547 (1)